Free Trial
NASDAQ:ANEB

Anebulo Pharmaceuticals Q3 2025 Earnings Report

Anebulo Pharmaceuticals logo
$1.05 +0.07 (+7.68%)
As of 03:17 PM Eastern

Anebulo Pharmaceuticals EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.05
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Anebulo Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Anebulo Pharmaceuticals Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Anebulo Pharmaceuticals' Q4 2025 earnings is scheduled for Wednesday, May 21, 2025

Anebulo Pharmaceuticals Earnings Headlines

Washington Is Broke—and Eyeing Your Savings Next
Washington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.
See More Anebulo Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anebulo Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anebulo Pharmaceuticals and other key companies, straight to your email.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals (NASDAQ:ANEB), a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

View Anebulo Pharmaceuticals Profile

More Earnings Resources from MarketBeat